chartexchange

OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

Newsfile | Nov 10, 2026 8:15 AM EST

Submission expected to be accepted in the fourth quarter of 2026Potential early market access decision expected from MHRA in the first quarter of 2027Grasonville, Maryland--(Newsfile Corp. - November 10, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has initiated a Conditional Marketing Authorisation Application (CMAA) process with the U.K. Medicines and...

Read original article